PROGRAM - 5th International Keloid Symposium - Shanghai, China
Time
Speaker
Title
DAY 1
Friday June 6, 2025
Weil Liu, MD, PhD
Xiaoli Wu, MD, PhD
Dan Deng, MD
Opening of the 5th International Keloid Symposium
Co-Chair: Michael H Tirgan, MD
Panel Discussion and Q/A
10:30-10:45
Coffee Break
Co-Chair: Frank Nissen, MD, PhD
Panel Discussion and Q/A
12:30-13:30
Lunch Break
Co-Chair:
15:00 – 15:30
Coffee Break
15:30 – 17:00
Co-Chair:
Time
Speaker
Title
DAY 2
Saturday June 7, 2025
Co-Chair:
Yixin Zhang, MD
Molecular and immune-mechanism of keloid development.
Jong Hee Lee, MD, PhD
In Vitro Model for Keloids: 3D Spheroid with fibroblasts and endothelial cells.
Zhilian Qin, MD
Inhibition ENO1 expression targets the glycolytic and lactylation to regulate keloid fibroblast function.
Chenyu Huang, MD
Asporin inhibits collagen matrix-mediated intercellular mechanocommunications between fibroblasts during keloid progression.
Panel Discussion and Q/A
10:30-10:45
Coffee Break
Co-Chair:Jonathan Tsao, MD
Jonathan Tsao, MD
Adjuvant Radiotherapy for the Treatment of Keloids.
Henry Weatherburn, PhD
A Data-Based Approach to a Keloid Post-Excisional Radiotherapy Treatment (PERT) Pathway.
Zhongling Qiu, MD
Isotope Therapy to Prevent Post-Surgical Keloid Recurrence.
Fuquan Zhang, MD
Clinical Outcomes of Electronic Beam Irradiation for Post-Surgical Keloids in a Large-scale Investigation.
Henry Weatherburn, PhD
A 15 Year Single Centre Audit of the Outcome of Fractionated Superficial X-Ray Radiotherapy Treatment of Recurrent Keloid Tumours.
Panel Discussion and Q/A
12:30-13:30
Lunch Break
Co-Chair:
Chunmei Wang, MD
Clinical Application of Punch Therapy in Keloids.
Renliang He, MD
Trephination Technique in Treating Keloids.
Wei Liu, MD, PhD
Punch Surgery and HA Hydrogel Drug Delivery for Keloid Treatment
15:00 – 15:30
Coffee Break
15:30 – 17:00
Co-Chair:
Qi Yin, MD
Current Practices and Keloid Treatment Approaches.
Lee Jong Hee, MD, PhD
Reevaluation of Treatment of Keloids Based on the Pathogenesis and Clinical Condition.
Binrong Zhou, MD
Novel Needle-Type Electrocoagulation and Combination Pharmacotherapy: Basic and Clinical Studies on Efficacy and Safety in Treating Keloids.
Xiaoli Wu, MD, PhD
LCR Technique for Keloid Treatment
16:30-17:00
TBD<br>
The Annual Jouni Uitto, MD, PhD International Visiting Professorship and Lecture in Molecular Dermatology
Time
Speaker
Title
DAY 3
Sunday June 8, 2025
Co-Chair: Wei Liu, MD, PhD
Michael H. Tirgan, MD
Pediatric Keloids: Case Review, Clinical Patterns, and Treatment Recommendations.
Xiqiao Wang, MD
Microbiome Dysbiosis Dominated by Rhodococcus Occurs in Keloids
TBD
TBD
TBD
TBD
Panel Discussion and Q/A
10:30-10:45
Coffee Break
Co-Chair:
Tony Chan, MD, PhD
Intralesional Cryosurgery for Keloid Treatment.
Cecilla Li, MD
Novel Concept and Clinical Practice of Keloid Pressure Therapy
Michael H. Tirgan, MD
Localized Chemotherapy for Keloids: Clinical Applications and Efficacy.
Patricia Yap, MD
Keloid Disorder and Telemedicine – a Patient’s Journey.
Nanzhe Yu, MD
Understanding and Clinical Practice of Vascular Abnormalities in Keloid Disease.
John Glees, MD, FRCP
Case Studies of Patient Outcomes of Re-Treatment of Recurrent Keloid Tumours by Fractionated Superficial X-Ray Radiotherapy.
Panel Discussion and Q/A
12:30-13:30
Lunch Break
Co-Chair:
Akash Gunjan, PhD
Leveraging Machine Learning Using Clinical Data to Predict Response to Intralesional Steroids in Keloid Patients.
Qi Yin, MD
The biodistribution of Triamcinolone Acetonide Injections in Severe Keloids: An Exploratory Three-Dimensional Fluorescent Cryomicrotome Study.
Lian Zhang, MD
Integrated Multi-Omics Unveils the Epigenetic Landscape in the Pathogenesis of Keloid.
Lamont Jones, MD, MBA
Clinical Biomarkers: The Future of Keloid Disease Diagnosis and Therapy.
Tianhao Li, MD
TWIST1 Promote TGF-β Receptor I in Keloid Fibroblasts via Regulating the Stability of MEF2A.
Akash Gunjan, PhD
Repurposed Combination Drug Therapies for Keloid Disorder.
15:15 – 15:30
Coffee Break
15:30 – 17:00
Co-Chair:
Tianhao Li, MD
TWIST1 promote TGF-β Receptor I in keloid fibroblasts via regulating the stability of MEF2A.
Yixin Sun, MD
Single-cell RNA sequencing revealed key factors of EMT to Promote Fibroblasts Activation and Immune Infiltration in Keloids
Junxian Wen, MD
Insights from Comparing Blood Perfusion Metrics and Vancouver Scar Scale in Keloid Assessment.
Junxian Wen, MD
Coping Tendencies Play Partial Mediating Role Between Social Support and Anxiety/Depression Among Chinese Keloid Patients.
Akash Gunjan, PhD
Repurposed Combination Therapeutics for Keloid Disorder.
